FDA Approves Radiation Device for Skin Cancer and Other Lesions
Posted: Friday, October 11, 2019
On October 1, the U.S. Food and Drug Administration (FDA) approved CivaDerm for intraoperative or surface radiation to treat skin cancer and other lesions. The polymer-encapsulated brachytherapy device can be applied like a bandage to provide a low-dose–rate brachytherapy treatment option for patients with skin cancer. This device is designed with gold shielding, enabling one side of the radiation device alone to be active.
A physician places the active side of the device on the targeted area. Patients wear the bandage over a 5-day window. CivaDerm allows health-care providers to offer radiation therapy at a lower cost without the need for purchasing expensive equipment. It also enables patients to reduce the number of visits to a facility during treatment.
